by Truveta staff | Jun 20, 2023 | Technology
The Centers for Disease Control and Prevention reports that cardiovascular (CV) disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the US, with 805,000 dying yearly. Developing improved cardiovascular therapies is...
by Terry Myerson, CEO | Jun 20, 2023 | Technology
I can’t imagine our country without the FDA continuously assessing the safety and efficacy of medical products, or our government without the CDC monitoring and guiding public health choices. And yet, we all saw during the pandemic that there is a clear opportunity...
by Truveta staff | Jun 15, 2023 | Data
We are entering a new era of Alzheimer’s Disease research. Researchers from the University of Tsukuba in Japan along with IBM Research have recently developed a mobile app to detect Alzheimer’s using speech data. New research suggests deep brain stimulation while...
by Truveta Research | Jun 6, 2023 | Research, Research Insights
Beginning in Fall 2022, the news media has reported extensively on the use of Glucagon-like peptide-1 receptor agonist (GLP-1s) for weight loss (Belluz, 2023). Physicians have taken to TikTok to promote GLP-1s for weight loss, and celebrities & influencers – such...
